Search Results
Chen Wang
Chen Wang
Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Chen Wang in
Google Scholar
PubMed
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Chen Wang in
Google Scholar
PubMed
Xin Zhang
Xin Zhang
Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Xin Zhang in
Google Scholar
PubMed
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Xin Zhang in
Google Scholar
PubMed
Xue Yang
Xue Yang
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China
Search for other papers by Xue Yang in
Google Scholar
PubMed
Search for other papers by Xue Yang in
Google Scholar
PubMed
Hui Li
Hui Li
Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Hui Li in
Google Scholar
PubMed
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Hui Li in
Google Scholar
PubMed
Ruixue Cui
Ruixue Cui
Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Ruixue Cui in
Google Scholar
PubMed
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Ruixue Cui in
Google Scholar
PubMed
Wenmin Guan
Wenmin Guan
Department of Radiology, Peking Union Medical College Hospital, Beijing, China
Search for other papers by Wenmin Guan in
Google Scholar
PubMed
Search for other papers by Wenmin Guan in
Google Scholar
PubMed
Xin Li
Xin Li
Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, China
Search for other papers by Xin Li in
Google Scholar
PubMed
Search for other papers by Xin Li in
Google Scholar
PubMed
Zhaohui Zhu
Zhaohui Zhu
Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Zhaohui Zhu in
Google Scholar
PubMed
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Zhaohui Zhu in
Google Scholar
PubMed
Yansong Lin
Yansong Lin
Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Yansong Lin in
Google Scholar
PubMed
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Search for other papers by Yansong Lin in
Google Scholar
PubMed
dedifferentiation of thyroid cancer ( Xing 2007 ). Similarly, patients harbouring both BRAF V600E and TERT mutation were refractory to radioactive iodine, which may result in unfavourable prognosis ( Yang et al . 2017 ). Previous studies have reported the
Marcia S Brose
Marcia S Brose
Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Stellar-Chance Laboratories Mezzanine, Philadelphia, Pennsylvania, USA
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Johannes Smit
Johannes Smit
Department of Internal Medicine, Radboud University Nijmegen Medical Center, 463 General Internal Medicine, Nijmegen, Netherlands
Search for other papers by Johannes Smit in
Google Scholar
PubMed
Search for other papers by Johannes Smit in
Google Scholar
PubMed
Chia-Chi Lin
Chia-Chi Lin
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
Search for other papers by Chia-Chi Lin in
Google Scholar
PubMed
Search for other papers by Chia-Chi Lin in
Google Scholar
PubMed
Fabian Pitoia
Fabian Pitoia
Division of Endocrinology, Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina
Search for other papers by Fabian Pitoia in
Google Scholar
PubMed
Search for other papers by Fabian Pitoia in
Google Scholar
PubMed
Marc Fellous
Marc Fellous
Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA
Search for other papers by Marc Fellous in
Google Scholar
PubMed
Search for other papers by Marc Fellous in
Google Scholar
PubMed
Yoriko DeSanctis
Yoriko DeSanctis
Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA
Search for other papers by Yoriko DeSanctis in
Google Scholar
PubMed
Search for other papers by Yoriko DeSanctis in
Google Scholar
PubMed
Martin Schlumberger
Martin Schlumberger
Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy and Université Paris Saclay, Villejuif, France
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Masayuki Tori
Masayuki Tori
Department of Endocrine Surgery, Osaka Police Hospital, Tennoujiku, Osaka, Japan
Search for other papers by Masayuki Tori in
Google Scholar
PubMed
Search for other papers by Masayuki Tori in
Google Scholar
PubMed
Iwao Sugitani
Iwao Sugitani
Department of Endocrine Surgery, Nippon Medical School Graduate School of Medicine, Bunkyo-Ku, Tokyo, Japan
Search for other papers by Iwao Sugitani in
Google Scholar
PubMed
Search for other papers by Iwao Sugitani in
Google Scholar
PubMed
-term outcome data, is needed to guide treatment decisions ( Carhill et al. 2015 ). Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer – an Observational Study to Assess the Use of Multikinase Inhibitors (RIFTOS MKI) is a
Jennifer A Woyach
Jennifer A Woyach
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA
Search for other papers by Jennifer A Woyach in
Google Scholar
PubMed
Search for other papers by Jennifer A Woyach in
Google Scholar
PubMed
Manisha H Shah
Manisha H Shah
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA
Search for other papers by Manisha H Shah in
Google Scholar
PubMed
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA
Search for other papers by Manisha H Shah in
Google Scholar
PubMed
and increase the uptake of radioactive iodine into thyroid cancer cells ( Marsee et al . 2004 ). It has also been shown that levels of Hsp 90, rather than histologic subtype, determine the cytotoxic response to the agent in thyroid cancer cell lines
Marie-Claude Hofmann
Marie-Claude Hofmann
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Marie-Claude Hofmann in
Google Scholar
PubMed
Search for other papers by Marie-Claude Hofmann in
Google Scholar
PubMed
Muthusamy Kunnimalaiyaan
Muthusamy Kunnimalaiyaan
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Muthusamy Kunnimalaiyaan in
Google Scholar
PubMed
Search for other papers by Muthusamy Kunnimalaiyaan in
Google Scholar
PubMed
Jennifer R Wang
Jennifer R Wang
Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Jennifer R Wang in
Google Scholar
PubMed
Search for other papers by Jennifer R Wang in
Google Scholar
PubMed
Naifa L Busaidy
Naifa L Busaidy
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Naifa L Busaidy in
Google Scholar
PubMed
Search for other papers by Naifa L Busaidy in
Google Scholar
PubMed
Steven I Sherman
Steven I Sherman
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Steven I Sherman in
Google Scholar
PubMed
Search for other papers by Steven I Sherman in
Google Scholar
PubMed
Stephen Y Lai
Stephen Y Lai
Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Stephen Y Lai in
Google Scholar
PubMed
Search for other papers by Stephen Y Lai in
Google Scholar
PubMed
Mark Zafereo
Mark Zafereo
Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Mark Zafereo in
Google Scholar
PubMed
Search for other papers by Mark Zafereo in
Google Scholar
PubMed
Maria E Cabanillas
Maria E Cabanillas
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Maria E Cabanillas in
Google Scholar
PubMed
Search for other papers by Maria E Cabanillas in
Google Scholar
PubMed
with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial . Lancet: Oncology 17 1272 – 1282 . ( https://doi.org/10.1016/S1470
Sarah E Mayson
Sarah E Mayson
Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
Search for other papers by Sarah E Mayson in
Google Scholar
PubMed
Search for other papers by Sarah E Mayson in
Google Scholar
PubMed
Christine M Chan
Christine M Chan
Section of Endocrinology, Department of Pediatrics, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA
Search for other papers by Christine M Chan in
Google Scholar
PubMed
Search for other papers by Christine M Chan in
Google Scholar
PubMed
Bryan R Haugen
Bryan R Haugen
Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
University of Colorado Cancer Center, Aurora, Colorado, USA
Search for other papers by Bryan R Haugen in
Google Scholar
PubMed
University of Colorado Cancer Center, Aurora, Colorado, USA
Search for other papers by Bryan R Haugen in
Google Scholar
PubMed
calculation. Radioactive iodine refractory disease The ATA defines RAI-refractory DTC in patients with structural evident disease after appropriate iodine preparation and TSH stimulation in one of four ways: (1) no uptake outside the thyroid bed at the
Jaume Capdevila
Jaume Capdevila
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Lara Iglesias
Lara Iglesias
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Lara Iglesias in
Google Scholar
PubMed
Search for other papers by Lara Iglesias in
Google Scholar
PubMed
Irene Halperin
Irene Halperin
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Irene Halperin in
Google Scholar
PubMed
Search for other papers by Irene Halperin in
Google Scholar
PubMed
Ángel Segura
Ángel Segura
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Ángel Segura in
Google Scholar
PubMed
Search for other papers by Ángel Segura in
Google Scholar
PubMed
Javier Martínez-Trufero
Javier Martínez-Trufero
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Javier Martínez-Trufero in
Google Scholar
PubMed
Search for other papers by Javier Martínez-Trufero in
Google Scholar
PubMed
Maria Ángeles Vaz
Maria Ángeles Vaz
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Maria Ángeles Vaz in
Google Scholar
PubMed
Search for other papers by Maria Ángeles Vaz in
Google Scholar
PubMed
Jesús Corral
Jesús Corral
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Jesús Corral in
Google Scholar
PubMed
Search for other papers by Jesús Corral in
Google Scholar
PubMed
Gabriel Obiols
Gabriel Obiols
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Gabriel Obiols in
Google Scholar
PubMed
Search for other papers by Gabriel Obiols in
Google Scholar
PubMed
Enrique Grande
Enrique Grande
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Enrique Grande in
Google Scholar
PubMed
Search for other papers by Enrique Grande in
Google Scholar
PubMed
Juan Jose Grau
Juan Jose Grau
Medical Oncology Department, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Medical Oncology Department, Endocrinology Department, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain
Search for other papers by Juan Jose Grau in
Google Scholar
PubMed
Search for other papers by Juan Jose Grau in
Google Scholar
PubMed
Josep Tabernero
Josep Tabernero
Search for other papers by Josep Tabernero in
Google Scholar
PubMed
Search for other papers by Josep Tabernero in
Google Scholar
PubMed
(3) Arthromyalgia 1 (3) Elevated transaminases 1 (3) 1 (3) Discussion Until recently, medical management of advanced thyroid cancer refractory to standard treatments has been particularly challenging. Classical DNA-damaging drugs have demonstrated
Mehtap Derya Aydemirli
Mehtap Derya Aydemirli
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Mehtap Derya Aydemirli in
Google Scholar
PubMed
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Mehtap Derya Aydemirli in
Google Scholar
PubMed
Jaap D H van Eendenburg
Jaap D H van Eendenburg
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Jaap D H van Eendenburg in
Google Scholar
PubMed
Search for other papers by Jaap D H van Eendenburg in
Google Scholar
PubMed
Tom van Wezel
Tom van Wezel
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Tom van Wezel in
Google Scholar
PubMed
Search for other papers by Tom van Wezel in
Google Scholar
PubMed
Jan Oosting
Jan Oosting
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Jan Oosting in
Google Scholar
PubMed
Search for other papers by Jan Oosting in
Google Scholar
PubMed
Willem E Corver
Willem E Corver
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Willem E Corver in
Google Scholar
PubMed
Search for other papers by Willem E Corver in
Google Scholar
PubMed
Ellen Kapiteijn
Ellen Kapiteijn
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Ellen Kapiteijn in
Google Scholar
PubMed
Search for other papers by Ellen Kapiteijn in
Google Scholar
PubMed
Hans Morreau
Hans Morreau
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Hans Morreau in
Google Scholar
PubMed
Search for other papers by Hans Morreau in
Google Scholar
PubMed
M Janakiraman M Solit D Knauf JA Tuttle RM 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 . Cancer Research 69
Thomas A Werner
Thomas A Werner
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Thomas A Werner in
Google Scholar
PubMed
Search for other papers by Thomas A Werner in
Google Scholar
PubMed
Inga Nolten
Inga Nolten
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Inga Nolten in
Google Scholar
PubMed
Search for other papers by Inga Nolten in
Google Scholar
PubMed
Levent Dizdar
Levent Dizdar
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Levent Dizdar in
Google Scholar
PubMed
Search for other papers by Levent Dizdar in
Google Scholar
PubMed
Jasmin C Riemer
Jasmin C Riemer
Institute of Pathology, Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Jasmin C Riemer in
Google Scholar
PubMed
Search for other papers by Jasmin C Riemer in
Google Scholar
PubMed
Sina C Schütte
Sina C Schütte
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Sina C Schütte in
Google Scholar
PubMed
Search for other papers by Sina C Schütte in
Google Scholar
PubMed
Pablo E Verde
Pablo E Verde
Coordination Centre for Clinical Trials, Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Pablo E Verde in
Google Scholar
PubMed
Search for other papers by Pablo E Verde in
Google Scholar
PubMed
Katharina Raba
Katharina Raba
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Katharina Raba in
Google Scholar
PubMed
Search for other papers by Katharina Raba in
Google Scholar
PubMed
Matthias Schott
Matthias Schott
Division of Endocrinology, Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Matthias Schott in
Google Scholar
PubMed
Search for other papers by Matthias Schott in
Google Scholar
PubMed
Wolfram T Knoefel
Wolfram T Knoefel
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Wolfram T Knoefel in
Google Scholar
PubMed
Search for other papers by Wolfram T Knoefel in
Google Scholar
PubMed
Andreas Krieg
Andreas Krieg
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Duesseldorf, Germany
Search for other papers by Andreas Krieg in
Google Scholar
PubMed
Search for other papers by Andreas Krieg in
Google Scholar
PubMed
Jarzab B Elisei R Siena S Bastholt L la Fouchardiere de C Pacini F Paschke R Shong YK , 2014 Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet
Fabián Pitoia
Fabián Pitoia
Search for other papers by Fabián Pitoia in
Google Scholar
PubMed
Search for other papers by Fabián Pitoia in
Google Scholar
PubMed
RECIST1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma . Oncology Letters 6 480 – 486 . ( doi:10.3892/ol.2013.1424 ). Shen CT Qiu Z
Fernanda Vaisman
Fernanda Vaisman
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Denise P Carvalho
Denise P Carvalho
Endocrinology Service, Laboratório de Fosiologia Endócrina Doris Rosental, Endocrinology Service, National Cancer Institute, Brazil Praça da Cruz Vermelha, 23, 8° Floor, Centro, Rio de Janeiro, Rio de Janeiro, 20230-130, Brazil
Search for other papers by Denise P Carvalho in
Google Scholar
PubMed
Search for other papers by Denise P Carvalho in
Google Scholar
PubMed
Mario Vaisman
Mario Vaisman
Endocrinology Service, Laboratório de Fosiologia Endócrina Doris Rosental, Endocrinology Service, National Cancer Institute, Brazil Praça da Cruz Vermelha, 23, 8° Floor, Centro, Rio de Janeiro, Rio de Janeiro, 20230-130, Brazil
Search for other papers by Mario Vaisman in
Google Scholar
PubMed
Search for other papers by Mario Vaisman in
Google Scholar
PubMed
.21520 ). Anderson RT Linnehan JE Tongbram V Keating K Wirth LJ 2013 Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review . Thyroid 23 392 – 407 . ( doi
